Join
Live feed
·
PRReleasevia Quantisnow
Galmed Pharmaceuticals Ltd. logo

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

ByQuantisnow·Wall Street's wire, on your screen.
GLMD· Galmed Pharmaceuticals Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLMD (Galmed Pharmaceuticals Ltd.) and more on Quantisnow.